SCHEMBL3463637

SCHEMBL3463637

CCOc1c[c]ccc1OCC(=O)N(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
ALDH1A1 P00352 8/20 0.44
LMNA P02545 3/20 0.44
MAPT P10636 3/20 0.44
POLB P06746 2/20 0.44
SMN1; SMN2 Q16637 4/20 0.43
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
MAPK1 P28482 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
ESR1 P03372 1/20 0.42
KDM4E B2RXH2 4/20 0.40
HSD17B10 Q99714 4/20 0.40
HPGD P15428 3/20 0.40
TSHR P16473 1/20 0.39
ATM Q13315 1/20 0.39
PKM P14618 1/20 0.37
GAA P10253 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5460045 0.84 L3MBTL1 (0.65) GLAL3MBTL1ALDH1A1MAPTPOLB
SCHEMBL9024146 0.82 L3MBTL1 (0.45) GLAL3MBTL1ALDH1A1LMNAMAPT
SCHEMBL8224479 0.82 MEN1 (0.41) GLAALDH1A1LMNAPOLBSMN1; SMN2
SCHEMBL127280 0.82 ALDH1A1 (0.39) GLAL3MBTL1ALDH1A1MAPTPOLB
SCHEMBL10337148 0.78 ALDH1A1 (0.48) ALDH1A1LMNAMAPTSMN1; SMN2MEN1
SCHEMBL18297785 0.77 ALDH1A1 (0.56) ALDH1A1LMNAPOLBSMN1; SMN2MEN1
SCHEMBL4998751 0.76 KDM4E (0.41) GLAL3MBTL1ALDH1A1MAPTPOLB
SCHEMBL6718467 0.75 L3MBTL1 (0.50) GLAL3MBTL1ALDH1A1MAPTPOLB
SCHEMBL3463971 0.75 HTR7 (0.42) L3MBTL1ALDH1A1MAPTSMN1; SMN2NPSR1
SCHEMBL3483041 0.74 TSHR (0.52) ALDH1A1LMNAPOLBSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100240654-A1 HYDRAZIDE DERIVATIVES CLARK RICHARD 2010-09-23 US claimed
US-20080132507-A1 Hydrazide Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-06-05 US claimed
EP-1810965-A1 HYDRAZIDE DERIVATIVES Eisai R&D Management Co., Ltd. (JP) 2007-07-25 EP claimed
US-20100240654-A1 HYDRAZIDE DERIVATIVES CLARK RICHARD 2010-09-23 US disclosed
US-20080132507-A1 Hydrazide Derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-06-05 US disclosed
EP-1810965-A1 HYDRAZIDE DERIVATIVES Eisai R&D Management Co., Ltd. (JP) 2007-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240654-A1 HYDRAZIDE DERIVATIVES H1-10, H1-4, H1-3 GLA 780/4885L3MBTL1 895/4885ALDH1A1 192/4885
US-20080132507-A1 Hydrazide Derivatives H1-10, H1-4, H1-3 GLA 780/4885L3MBTL1 895/4885ALDH1A1 192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.